BCM
TEVA icon

Blume Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Blume Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-600
Closed -$13K – 226
2018
Q3 		$13K Hold
600
– – 0.01% 158
2018
Q2 		$15K Hold
600
– – 0.01% 155
2018
Q1 		$10K Hold
600
– – 0.01% 176
2017
Q4 		$11K Hold
600
– – 0.01% 185
2017
Q3 		$11K Sell
600
-118,980
-99% -$2.68M 0.01% 193
2017
Q2 		$3.97M Buy
119,580
+10,900
+10% +$337K 2.26% 19
2017
Q1 		$3.49M Buy
108,680
+25,565
+31% +$872K 2.02% 22
2016
Q4 		$3.01M Buy
+83,115
New +$3.32M 1.81% 24

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Blume Capital Management's TEVA Position: Q4 2018 in Review

Blume Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 600 shares — an estimated $13K sold.

Blume Capital Management first reported a position in TEVA in Q4 2016 and held it in 8 quarters. The position peaked at $3.97M in Q2 2017. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Blume Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Blume Capital Management sold 600 Teva Pharmaceuticals shares in Q4 2018, an estimated $13K.
  • Blume Capital Management first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 8 quarters.
  • Blume Capital Management's Teva Pharmaceuticals position peaked at $3.97M in Q2 2017.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Blume Capital Management's 13F filing for Q4 2018, filed 5 Feb 2019.